Combinations comprising epothilones and pharmaceutical uses...

Details Combinations comprising epothilones and pharmaceutical uses... Combinations comprising epothilones and pharmaceutical uses...

2008-01-24

2009-11-03

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S108000, C514S365000, C514S492000

Reexamination Certificate

active

07612052

ABSTRACT:
The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula Iwherein A represents O or NRN, wherein RNis hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

REFERENCES:
patent: 2409754 (1946-10-01), Henze
patent: 3475486 (1969-10-01), Irani et al.
patent: 3962432 (1976-06-01), Schmidt-Dunker
patent: 4746654 (1988-05-01), Breliere et al.
patent: 4814326 (1989-03-01), Rosini et al.
patent: 4927814 (1990-05-01), Gall et al.
patent: 5405994 (1995-04-01), Bonnery et al.
patent: 5583122 (1996-12-01), Benedict et al.
patent: 5849726 (1998-12-01), Brenner et al.
patent: 6302838 (2001-10-01), O'Reilly et al.
patent: 2002/0061866 (2002-05-01), Bataille et al.
patent: 2 775 187 (1999-08-01), None
patent: WO 94 14455 (1994-07-01), None
patent: WO 98 35958 (1998-08-01), None
patent: WO 99 01124 (1999-01-01), None
patent: WO 99 02514 (1999-01-01), None
patent: WO 99 39694 (1999-08-01), None
patent: WO 00 00485 (2000-01-01), None
patent: WO 00 18439 (2000-04-01), None
patent: WO 00 49019 (2000-08-01), None
patent: WO 00 59485 (2000-10-01), None
patent: WO 00 71104 (2000-11-01), None
patent: WO 01 49295 (2001-07-01), None
patent: WO 02 072085 (2002-09-01), None
Stearns M. E. et al., “Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice,” Invasion Metastasis, vol. 16(3), pp. 116-131 (1996).
Diel I. J. et al., “Reduction in new metastases in breast cancer with adjuvant clodronate treatment,” New England Journal of Medicine, vol. 339(6), pp. 357-363 (1998).
Wood J. M. et al. “PTK787/ZK 222584, A novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration,” Cancer Research, vol. 60(8), pp. 2178-2189 (2000).
Schmidt P. et al., Tatsaechlicher Nutzen oder nur kein Schaden? Bisphosphonate in der Onkologie, Pharmacie in unserer Zeit, Nr. 6, pp. 519-527 (2001) (only available in German Language).
Yano et al., “Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation,” Clinical Cancer Research, vol. 6(3), pp. 957-965 (2000).
Seiden M. V. et al., “Ovarian cancer,” Oncologist, vol. 6(4), pp. 327-332 (2001).
Gillis R.A. et al., “Depression of cardiac synpathetic nerve activity by diphenylhydantoin,” The Journal of Pharmacology and Experimental Therapeutics, vol. 179, pp. 599-610 (1971).
Quimby O. T. et al., “Tetrasodium carbonyldiphosphonate, synthesis, reactions, and spectral properties,” J. Org. Chem., vol. 32, pp. 4111-4114 (1967).
Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), Calabresi, et al, Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.

Affiliated with

Also associated with

Rating

Combinations comprising epothilones and pharmaceutical uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations comprising epothilones and pharmaceutical uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations comprising epothilones and pharmaceutical uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4138661